ERBB2 and breast carcinoma: However, it has been reported that HER2 overexpression is associated with reduced levels of major histocompatibility complex (HMC) class I molecules in several models, including murine fibroblasts [72], mammary carcinoma [73], human melanoma [74], esophageal squamous cell carcinoma (ESCC) [75] and breast cancer [76].